{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:55:28Z","timestamp":1786121728603,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"DOI":"10.7759\/cureus.114098","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:23:24Z","timestamp":1786083804000},"source":"Crossref","is-referenced-by-count":0,"title":["Faricimab in the Treatment of Retinal Disease: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Mahmoud","family":"Zeaiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadil","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koussay","family":"Gharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiona Maria Benedict","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Mchaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad A","family":"Hammoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Prevalence, pattern and risk factors of retinal diseases among an elderly population in Nepal: the Bhaktapur retina study","volume":"14","author":"Thapa R","year":"2020","unstructured":"Thapa R, Khanal S, Tan HS, Thapa SS, van Rens GH. Prevalence, pattern and risk factors of retinal diseases among an elderly population in Nepal: the Bhaktapur retina study. Clin Ophthalmol. 2020, 14:2109-18.","journal-title":"Clin Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-004-0262-2","article-title":"Incidence of patients presenting with exudative maculopathy and neovascular retinal disease in an urban population","volume":"116","author":"Ergun E","year":"2004","unstructured":"Ergun E, Abramov A, Zawinka C, Stur M. Incidence of patients presenting with exudative maculopathy and neovascular retinal disease in an urban population. Wien Klin Wochenschr. 2004, 116:737-43. 10.1007\/s00508-004-0262-2","journal-title":"Wien Klin Wochenschr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2066169","article-title":"New frontiers of retinal therapeutic intervention: a critical analysis of novel approaches","volume":"54","author":"Nanegrungsunk O","year":"2022","unstructured":"Nanegrungsunk O, Au A, Sarraf D, Sadda SR. New frontiers of retinal therapeutic intervention: a critical analysis of novel approaches. Ann Med. 2022, 54:1067-80. 10.1080\/07853890.2022.2066169","journal-title":"Ann Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119591","article-title":"Current treatments for diabetic macular edema","volume":"24","author":"Tatsumi T","year":"2023","unstructured":"Tatsumi T. Current treatments for diabetic macular edema. Int J Mol Sci. 2023, 24:9591. 10.3390\/ijms24119591","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/2515841419831152","article-title":"Polypoidal choroidal vasculopathy: a comprehensive clinical update","volume":"11","author":"Kumar A","year":"2019","unstructured":"Kumar A, Kumawat D, Sundar MD, et al.. Polypoidal choroidal vasculopathy: a comprehensive clinical update. Ther Adv Ophthalmol. 2019, 11:2515841419831152. 10.1177\/2515841419831152","journal-title":"Ther Adv Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha FM","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, et al.. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retin Vitr. 2024, 10:5. 10.1186\/s40942-024-00525-9","journal-title":"Int J Retin Vitr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong TY","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al.. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024, 131:708-23. 10.1016\/j.ophtha.2023.12.026","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.11.015","article-title":"Resolution of angiographic macular leakage with faricimab versus aflibercept in patients with diabetic macular edema in YOSEMITE\/RHINE","volume":"9","author":"Goldberg RA","year":"2025","unstructured":"Goldberg RA, Mar FA, Csaky K, et al.. Resolution of angiographic macular leakage with faricimab versus aflibercept in patients with diabetic macular edema in YOSEMITE\/RHINE. Ophthalmol Retina. 2025, 9:515-26. 10.1016\/j.oret.2024.11.015","journal-title":"Ophthalmol Retina"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06531-9","article-title":"Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes","volume":"262","author":"Agostini H","year":"2024","unstructured":"Agostini H, Abreu F, Baumal CR, et al.. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefes Arch Clin Exp Ophthalmol. 2024, 262:3437-51. 10.1007\/s00417-024-06531-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.2-a.s3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration","volume":"24","author":"Wykoff CC","year":"2018","unstructured":"Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm. 2018, 24:S3-15. 10.18553\/jmcp.2018.24.2-a.s3","journal-title":"J Manag Care Spec Pharm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub4","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019, 3:CD005139. 10.1002\/14651858.CD005139.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara N","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016, 15:385-403. 10.1038\/nrd.2015.17","journal-title":"Nat Rev Drug Discov"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.12","article-title":"Diabetic retinopathy","volume":"2","author":"Wong TY","year":"2016","unstructured":"Wong TY, Cheung CM, Larsen M, Sharma S, Sim\u00f3 R. Diabetic retinopathy. Nat Rev Dis Primers. 2016, 2:16012. 10.1038\/nrdp.2016.12","journal-title":"Nat Rev Dis Primers"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.10.006","article-title":"Mechanisms of macular edema: beyond the surface","volume":"63","author":"Daruich A","year":"2018","unstructured":"Daruich A, Matet A, Moulin A, et al.. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018, 63:20-68. 10.1016\/j.preteyeres.2017.10.006","journal-title":"Prog Retin Eye Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05441-y","article-title":"Insights to Ang\/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases","volume":"22","author":"Sha L","year":"2024","unstructured":"Sha L, Zhao Y, Li S, Wei D, Tao Y, Wang Y. Insights to Ang\/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases. J Transl Med. 2024, 22:898. 10.1186\/s12967-024-05441-y","journal-title":"J Transl Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172161899","article-title":"Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo","volume":"99","author":"Lobov IB","year":"2002","unstructured":"Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A. 2002, 99:11205-10. 10.1073\/pnas.172161899","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003003","article-title":"The angiopoietin\/Tie pathway in retinal vascular diseases: a review","volume":"41","author":"Heier JS","year":"2021","unstructured":"Heier JS, Singh RP, Wykoff CC, et al.. The angiopoietin\/Tie pathway in retinal vascular diseases: a review. Retina. 2021, 41:1-19. 10.1097\/IAE.0000000000003003","journal-title":"Retina"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen AM","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond). 2021, 35:1305-16. 10.1038\/s41433-020-01377-x","journal-title":"Eye (Lond)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122109599","article-title":"Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF)","volume":"99","author":"Visconti RP","year":"2002","unstructured":"Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A. 2002, 99:8219-24. 10.1073\/pnas.122109599","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.11.023","article-title":"Anatomic outcomes with faricimab vs aflibercept in head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular age-related macular degeneration","volume":"132","author":"Cheung CM","year":"2025","unstructured":"Cheung CM, Lim JI, Priglinger S, et al.. Anatomic outcomes with faricimab vs aflibercept in head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular age-related macular degeneration. Ophthalmology. 2025, 132:519-26. 10.1016\/j.ophtha.2024.11.023","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula JT","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, et al.. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016, 8:1265-88. 10.15252\/emmm.201505889","journal-title":"EMBO Mol Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0670-1","article-title":"Faricimab: expanding horizon beyond VEGF","volume":"34","author":"Sharma A","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye (Lond). 2020, 34:802-4. 10.1038\/s41433-019-0670-1","journal-title":"Eye (Lond)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6962","article-title":"Endothelial destabilization by angiopoietin-2 via integrin \u03b21 activation","volume":"6","author":"Hakanpaa L","year":"2015","unstructured":"Hakanpaa L, Sipila T, Leppanen VM, et al.. Endothelial destabilization by angiopoietin-2 via integrin \u03b21 activation. Nat Commun. 2015, 6:5962. 10.1038\/ncomms6962","journal-title":"Nat Commun"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier JS","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al.. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022, 399:729-40. 10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff CC","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al.. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022, 399:741-55. 10.1016\/S0140-6736(22)00018-6","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni J","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, et al.. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019, 126:1155-70. 10.1016\/j.ophtha.2019.03.023","journal-title":"Ophthalmology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani AM","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, et al.. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020, 138:964-72. 10.1001\/jamaophthalmol.2020.2699","journal-title":"JAMA Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular pathogenesis of retinal and choroidal vascular diseases","volume":"49","author":"Campochiaro PA","year":"2015","unstructured":"Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015, 49:67-81. 10.1016\/j.preteyeres.2015.06.002","journal-title":"Prog Retin Eye Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.01.017","article-title":"Anatomic control with faricimab versus aflibercept in the YOSEMITE\/RHINE trials in diabetic macular edema","volume":"9","author":"Lim JI","year":"2025","unstructured":"Lim JI, Amador MJ, Dhoot DS, et al.. Anatomic control with faricimab versus aflibercept in the YOSEMITE\/RHINE trials in diabetic macular edema. Ophthalmol Retina. 2025, 9:655-66. 10.1016\/j.oret.2025.01.017","journal-title":"Ophthalmol Retina"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20250304-01","article-title":"Early outcomes after initiation of faricimab in patients with diabetic macular edema","volume":"56","author":"Borkar DS","year":"2025","unstructured":"Borkar DS, Tabano DC, Ali FS, et al.. Early outcomes after initiation of faricimab in patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2025, 56:478-86. 10.3928\/23258160-20250304-01","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S381503","article-title":"Faricimab for treatment-resistant diabetic macular edema","volume":"16","author":"Rush RB","year":"2022","unstructured":"Rush RB, Rush SW. Faricimab for treatment-resistant diabetic macular edema. Clin Ophthalmol. 2022, 16:2797-801. 10.2147\/OPTH.S381503","journal-title":"Clin Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani AM","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al.. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024, 131:914-26. 10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.05.004","article-title":"Outcomes by faricimab treatment interval at week 48 of TENAYA-LUCERNE phase III trials in neovascular age-related macular degeneration","volume":"9","author":"London NJ","year":"2025","unstructured":"London NJ, Cheung CM, Michels S, et al.. Outcomes by faricimab treatment interval at week 48 of TENAYA-LUCERNE phase III trials in neovascular age-related macular degeneration. Ophthalmol Retina. 2025, 9:1081-9. 10.1016\/j.oret.2025.05.004","journal-title":"Ophthalmol Retina"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.07.020","article-title":"Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab","volume":"9","author":"Sim SY","year":"2025","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, et al.. Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retina. 2025, 9:22-30. 10.1016\/j.oret.2024.07.020","journal-title":"Ophthalmol Retina"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.10.018","article-title":"Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration","volume":"8","author":"Pandit SA","year":"2024","unstructured":"Pandit SA, Momenaei B, Wakabayashi T, et al.. Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2024, 8:360-6. 10.1016\/j.oret.2023.10.018","journal-title":"Ophthalmol Retina"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-001967","article-title":"Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations","volume":"10","author":"Wong DT","year":"2025","unstructured":"Wong DT, Aboobaker S, Maberley D, Sharma S, Yoganathan P. Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations. BMJ Open Ophthalmol. 2025, 10:001967. 10.1136\/bmjophth-2024-001967","journal-title":"BMJ Open Ophthalmol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.03.005","article-title":"Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials","volume":"9","author":"Danzig CJ","year":"2025","unstructured":"Danzig CJ, Dinah C, Ghanchi F, et al.. Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials. Ophthalmol Retina. 2025, 9:848-59. 10.1016\/j.oret.2025.03.005","journal-title":"Ophthalmol Retina"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.101027","article-title":"Standardization of imaging criteria for detecting macular fibrosis in neovascular age-related macular degeneration","volume":"6","author":"Chakravarthy U","year":"2026","unstructured":"Chakravarthy U, Csincsik L, Teo KY, et al.. Standardization of imaging criteria for detecting macular fibrosis in neovascular age-related macular degeneration. Ophthalmol Sci. 2026, 6:101027. 10.1016\/j.xops.2025.101027","journal-title":"Ophthalmol Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-024-01078-y","article-title":"Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial","volume":"68","author":"Shimura M","year":"2024","unstructured":"Shimura M, Oh H, Ueda T, et al.. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial. Jpn J Ophthalmol. 2024, 68:511-22. 10.1007\/s10384-024-01078-y","journal-title":"Jpn J Ophthalmol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni R","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, et al.. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. Ophthalmology. 2024, 131:950-60. 10.1016\/j.ophtha.2024.01.029","journal-title":"Ophthalmology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00703-3","article-title":"Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion","volume":"11","author":"Hirakata T","year":"2025","unstructured":"Hirakata T, Toride A, Ashikaga K, et al.. Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion. Int J Retin Vitr. 2025, 11:79. 10.1186\/s40942-025-00703-3","journal-title":"Int J Retin Vitr"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-025-01247-3","article-title":"Aflibercept 8 mg versus faricimab treat-and-extend for diabetic macular edema or neovascular age-related macular degeneration: a Bayesian fixed-effect network meta-analysis of clinical trials","volume":"14","author":"Friedman SM","year":"2025","unstructured":"Friedman SM, Xu Y, Sherman S, et al.. Aflibercept 8 mg versus faricimab treat-and-extend for diabetic macular edema or neovascular age-related macular degeneration: a Bayesian fixed-effect network meta-analysis of clinical trials. Ophthalmol Ther. 2025, 14:2919-36. 10.1007\/s40123-025-01247-3","journal-title":"Ophthalmol Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1346322","article-title":"Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population","volume":"3","author":"Ibrahim FN","year":"2024","unstructured":"Ibrahim FN, Teo KY, Tan TE, et al.. Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population. Front Ophthalmol (Lausanne). 2024, 3:1346322. 10.3389\/fopht.2023.1346322","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/aos.16797","article-title":"Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis","volume":"103","author":"Arnold-Vangsted A","year":"2025","unstructured":"Arnold-Vangsted A, Schou MG, Balaratnasingam C, et al.. Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Acta Ophthalmol. 2025, 103:247-56. 10.1111\/aos.16797","journal-title":"Acta Ophthalmol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-06755-3","article-title":"Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD","volume":"263","author":"Huber AL","year":"2025","unstructured":"Huber AL, Bauer A, Beirer J, et al.. Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD. Graefes Arch Clin Exp Ophthalmol. 2025, 263:1259-67. 10.1007\/s00417-025-06755-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03980-2","article-title":"One-year outcomes of faricimab versus aflibercept treatment for polypoidal choroidal vasculopathy: a comparative study","volume":"39","author":"Cho J","year":"2025","unstructured":"Cho J, Han HY, Park S, Kim JH, Cho HJ. One-year outcomes of faricimab versus aflibercept treatment for polypoidal choroidal vasculopathy: a comparative study. Eye (Lond). 2025, 39:2893-8. 10.1038\/s41433-025-03980-2","journal-title":"Eye (Lond)"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S527787","article-title":"Switching to faricimab for polypoidal choroidal vasculopathy with real-world outcomes in refractory cases - the FAR-PEARL study report 1","volume":"19","author":"Fong KC","year":"2025","unstructured":"Fong KC, Wong WJ, Wong HS, Ling KP, Fong SN, Shunmugam M. Switching to faricimab for polypoidal choroidal vasculopathy with real-world outcomes in refractory cases - the FAR-PEARL study report 1. Clin Ophthalmol. 2025, 19:2475-85. 10.2147\/OPTH.S527787","journal-title":"Clin Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/498098-faricimab-in-the-treatment-of-retinal-disease-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:23:25Z","timestamp":1786083805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/498098-faricimab-in-the-treatment-of-retinal-disease-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.114098","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}